CFA differentially modulates the transcription of inflammasome-related genes and the administration of E2 increases the expression of ERα and Nlrp1 together with NFKB1, a key molecule in the activation of the inflammasomes. Finally, an analysis using the web interface GeneMANIA revealed an interaction between several genes, indicating a functional correlation in this model.
Subjects (n = 42) with a body mass index (BMI) ≥30 kg/m2 who received Anfepramone 75 mg/day for six months were studied. Relative gene expression was quantified by real‐time PCR. Anthropometric and biochemical parameters were also measured. NLRP3, TXNIP, TLR4 and LEP expression levels increased after Anfepramone treatment (p ≤0.05). Parameters such as BMI and glucose concentration decreased after the period of treatment (p ≤0.01), whereas cholesterol and LDL cholesterol concentrations increased (p ≤0.01). Anfepramone treatment was effective for weight loss; however lipid profile was perturbed. Expression changes might be due to the raised on free fatty acids (FFA) which produce reactive oxygen species (ROS). ROS activate NLRP3 per se and through TXNIP, while FFA activate TLR4 leading to priming process. On the other hand the data highlight LEP high expression level being that the mechanism described is by central nervous system stimulation. Here we show the first results on expression of inflammatory genes after an obesity pharmacologic treatment; this knowledge will be helpful to improve drug management and to avoid secondary effects. We acknowledge Instituto Politécnico Nacional for its support to 20111112 project. We thank Productos Medix S.A. de C.V. for providing the Anfepramone treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.